...
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Expression of Her2eu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
【24h】

Expression of Her2eu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.

机译:Her2 / neu,类固醇受体(ER和PR),Ki67和p53在与导管原位癌(DCIS)相关的浸润性乳腺导管癌中的表达与仅浸润性乳腺癌相比的表达。

获取原文
获取原文并翻译 | 示例
           

摘要

AIMS: (a) To assess the expression patterns of HER2eu, steroid receptors (ER and PR), Ki67 and p53 in invasive ductal cancer (IDC) and IDC associated with carcinoma in situ (IDC/DCIS) and (b) to determine if there is a differential expression of these molecular markers between IDC and IDC/DCIS. MATERIALS AND METHODS: Paraffin-fixed breast cancer samples, diagnosed with only one histological invasive tumor (IDC (n=130), and IDC/DCIS (n=36) were analyzed by immunohistochemical means. The non-parametric Mann-Whitney and chi2 tests were used to evaluate any statistical differences between different groups. Significance was assumed at p<0.05. RESULTS: A significant increase of the tumor grading was observed between IDC and IDC/DCIS (p<0.05). Her2eu amplification was demonstrated in 49.6% of IDC compared to 31% of IDC/DCIS (p<0.05). ER expression showed no statistical differences between IDC and IDC/DCIS. The PR expression was demonstrated in 71% of IDC with significantly lower intensity than IDC/DCIS (p<0.05). The Ki67 expression was significantly higher (p<0.05) in IDC cases (64%) versus IDC/DCIS (49.7%). No differences were observed between IDC and IDC/DCIS for p53 expression. CONCLUSION: We demonstrated significantly different expression patterns of Her2eu, PR and Ki67 in IDC versus IDC/DCIS. Since these molecular markers play important roles in carcinogenesis and tumor progression, IDC/DCIS could be an important subtype of mammary invasive ductal cancer. Differences in expression of the evaluated markers might suggest a higher malignant potential of invasive carcinomas alone. The lower expression of Her2eu and Ki67 in IDC/DCIS could implicate a less malignant behavior compared to a differentiated IDC. Additionally, these results might suggest that DCIS might be a malignant preform and the interaction with neoplastic tissue could result in an aggressive type of invasive tumor.
机译:目的:(a)评估HER2 / neu,类固醇受体(ER和PR),Ki67和p53在浸润性导管癌(IDC)和与原位癌相关的IDC(IDC / DCIS)中的表达模式,以及(b)确定这些分子标记在IDC和IDC / DCIS之间是否存在差异表达。材料与方法:采用免疫组织化学方法分析了仅诊断为一种组织学浸润性肿瘤(IDC(n = 130)和IDC / DCIS(n = 36))的石蜡固定乳腺癌样品,非参数Mann-Whitney和chi2。结果:IDC和IDC / DCIS之间的肿瘤分级显着增加(p <0.05),并证实了Her2 / neu扩增。 IDC为49.6%,而IDC / DCIS为31%(p <0.05)。ER表达在IDC和IDC / DCIS之间无统计学差异。PR表达在71%的IDC中得到证实,强度明显低于IDC / DCIS( p <0.05)。IDC患者(64%)的Ki67表达显着高于IDC / DCIS(49.7%)(p <0.05),IDC和IDC / DCIS在p53表达上没有差异。 Her2 / neu,PR和Ki67在I中的表达模式显着不同DC与IDC / DCIS。由于这些分子标记物在致癌和肿瘤进展中起着重要作用,因此IDC / DCIS可能是乳腺浸润性导管癌的重要亚型。被评估标志物表达的差异可能表明仅浸润性癌的恶性可能性更高。与分化的IDC相比,IDC / DCIS中Her2 / neu和Ki67的较低表达可能暗示了较少的恶性行为。此外,这些结果可能表明DCIS可能是恶性预制品,与肿瘤组织的相互作用可能导致侵袭性类型的浸润性肿瘤。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号